A detailed history of Crestwood Advisors Group LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Crestwood Advisors Group LLC holds 5,632 shares of VRTX stock, worth $2.56 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
5,632
Previous 5,533 1.79%
Holding current value
$2.56 Million
Previous $2.31 Million 14.14%
% of portfolio
0.06%
Previous 0.05%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

BUY
$392.81 - $485.53 $38,888 - $48,067
99 Added 1.79%
5,632 $2.64 Million
Q1 2024

May 08, 2024

BUY
$407.69 - $446.08 $177,752 - $194,490
436 Added 8.55%
5,533 $2.31 Million
Q4 2023

Jan 29, 2024

BUY
$343.0 - $410.68 $30,870 - $36,961
90 Added 1.8%
5,097 $2.07 Million
Q3 2023

Nov 15, 2023

BUY
$338.18 - $362.46 $1.69 Million - $1.81 Million
5,007 New
5,007 $1.74 Million
Q1 2021

Apr 21, 2021

SELL
$207.02 - $241.31 $254,634 - $296,811
-1,230 Closed
0 $0
Q4 2020

Feb 09, 2021

SELL
$207.01 - $276.09 $36,847 - $49,144
-178 Reduced 12.64%
1,230 $291,000
Q3 2020

Oct 06, 2020

BUY
$255.65 - $303.1 $766 - $909
3 Added 0.21%
1,408 $383,000
Q2 2020

Aug 14, 2020

SELL
$225.48 - $295.8 $1,578 - $2,070
-7 Reduced 0.5%
1,405 $407,000
Q1 2020

May 15, 2020

BUY
$199.77 - $247.81 $1,398 - $1,734
7 Added 0.5%
1,412 $336,000
Q4 2019

Feb 12, 2020

SELL
$166.71 - $223.91 $8,335 - $11,195
-50 Reduced 3.44%
1,405 $308,000
Q3 2019

Nov 13, 2019

SELL
$166.23 - $187.09 $166 - $187
-1 Reduced 0.07%
1,455 $247,000
Q2 2019

Aug 14, 2019

BUY
$164.61 - $190.37 $239,672 - $277,178
1,456 New
1,456 $267,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $117B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Crestwood Advisors Group LLC Portfolio

Follow Crestwood Advisors Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Crestwood Advisors Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Crestwood Advisors Group LLC with notifications on news.